drugset
drugset / Trial / NCT02111941

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02111941 ↗

Phase 0 Completed 19 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and chemotherapy. Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.

Timeline

Start
2014-04-14
Primary completion
2021-07-27
Completion
2021-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine Vaccine — Other

Indications

fallopian tube clear cell adenocarcinoma fallopian tube endometrioid tumor fallopian tube mucinous tumor fallopian tube transitional cell carcinoma ovarian clear cell cystadenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous cystadenocarcinoma ovarian seromucinous carcinoma ovarian serous cystadenocarcinoma ovarian transitional cell carcinoma primary peritoneal serous adenocarcinoma undifferentiated ovarian carcinoma